Arazlo (Tazarotene) Patent Expiration, LOE Window & CMS Spending

Arazlo (Tazarotene) by Bausch Health: FDA Orange Book LOE 2038-05-11, 8 AB generics, $3.3M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayN211882 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2038-05-11
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors8
2024 CMS Total Public Spend$3.3M
2024 Medicare Part D Spend$352K
2024 Medicaid Spend$3.0M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 18.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.